Peptic Ulcer Global Market Report 2024

The peptic ulcer market size has grown steadily in recent years. It will grow from $3.94 billion in 2023 to $4.1 billion in 2024 at a compound annual growth rate (CAGR) of 4.0%. The growth observed in the historical period can be ascribed to several factors, including an increased prevalence of Helicobacter pylori infection, a rise in the use of nonsteroidal anti-inflammatory drugs (NSAIDs), shifts in lifestyles and dietary habits, awareness campaigns and educational initiatives, and a heightened focus on stress management.

The peptic ulcer market size is expected to see steady growth in the next few years. It will grow to $4.69 billion in 2028 at a compound annual growth rate (CAGR) of 3.5%. The anticipated growth in the forecast period can be ascribed to emerging therapies and treatment modalities, a growing geriatric population, the integration of precision medicine, preventive measures, and health promotion, as well as ongoing research and clinical trials. Notable trends expected in the forecast period encompass digital health solutions, advancements in treatment modalities, a rising prevalence of Helicobacter pylori infection, the integration of diagnostic imaging technologies, and an increased utilization of combination therapies.

The anticipated rise in obesity prevalence is poised to drive the peptic ulcer market's growth. Obesity, characterized by excess body fat accumulation, typically results in a body mass index (BMI) of 30 or higher and can stem from genetic, environmental, and lifestyle factors such as poor diet and physical inactivity. This condition leads to increased stomach acid production, weakening the protective mucosal lining and contributing to peptic ulcer development. Moreover, excess weight promotes gut inflammation, further increasing the risk of peptic ulcers. Notably, the World Obesity Atlas 2022 report indicated that the global obesity estimate in 2020 was 764 million, projected to reach 892 million by 2025, underscoring the driving force of obesity on the peptic ulcer market.

The escalating rates of smoking are expected to fuel the peptic ulcer market's growth in the foreseeable future. Smoking, the inhalation of vapors from burning plant-based products such as tobacco or marijuana, is a well-established contributor to peptic ulcer disease. Smoking harms the stomach and duodenal linings, reduces blood supply to the stomach, and increases stomach acid production, elevating the incidence of peptic ulcers. For example, data from Quit Victoria in June 2023 highlighted a threefold increase in current cigarette smoking among 14-17-year-olds over four years, reaching 6.7% in 2022. Consequently, the rising smoking rates serve as a driving factor for the peptic ulcer market.

The substantial treatment costs represent a major impediment to the peptic ulcer market's growth during the forecast period. High treatment expenses for peptic ulcers pose a significant burden on patients, healthcare systems, and employers due to the costly medications administered in hospitals for complicated cases. As an illustration, information from the National Library of Medicine in February 2023 revealed that the annual cost of peptic ulcer disease in the USA is 5.65 billion USD, encompassing all medical expenditures. Consequently, the elevated treatment costs for peptic ulcers hinder the market's growth.

Companies engaged in the peptic ulcer market are actively developing innovative products and solutions, securing approval from regulatory agencies to gain a competitive edge. Drug development plays a pivotal role in managing and treating peptic ulcers, addressing symptom management, promoting healing, preventing complications, and treating underlying issues. Notably, in December 2021, the U.S. Food and Drug Administration granted approval to Dartisla ODT as the first medication specifically authorized for supplementing peptic ulcer disease treatment. Dartisla ODT, known for its anticholinergic properties, contains 1.7 mg of glycopyrrolate in each tablet.

In July 2022, Juvisé Pharmaceuticals, a France-based pharmaceutical company, acquired the global commercial rights to Pylera from AbbVie Inc. for $408 million (€400 million). Pylera, an antimicrobial tri-therapy, targets peptic ulcers caused by Helicobacter pylori (H. pylori) infection. This acquisition is expected to facilitate Juvisé Pharmaceuticals' expansion of its gastro-intestinal medicine product portfolio, serving as a strategic addition for geographic expansion. AbbVie Inc., a U.S.-based pharmaceutical company, specializes in providing various medications for diverse conditions, including peptic ulcers.

Major companies operating in the peptic ulcer market report are Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A, Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., CSL Limited, Boehringer Ingelheim International GmbH, Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Company, Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Limited, Hikma Pharmaceuticals PLC, Zydus Lifesciences, Lupin Limited, Livzon Pharmaceutical Group Inc., Yuhan Corporation, Torrent Pharmaceuticals Ltd., Daewoong Pharmaceutical Co. Ltd., Ilyang Pharmaceutical Co, Jiangsu Carephar Pharmaceutical Co Ltd.

North America was the largest region in the peptic ulcer market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peptic ulcer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa The countries covered in the peptic ulcer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The peptic ulcer market consists of revenues earned by entities by providing treatment services related to peptic ulcer such as surgeries, endoscopy, blood tests, and physical exams. The market value includes the value of related goods sold by the service provider or included within the service offering. The peptic ulcer market also includes sales of acid blockers, cytoprotective agents, bismuth subsalicylate, and mastic powder. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The primary disease indications consist of gastritis, gastric ulcers, duodenal ulcers, and gastroesophageal reflux disease (GERD). Gastritis is a medical condition characterized by inflammation, irritation, or erosion of the stomach lining. The typical approach to treating gastritis involves medications such as proton pump inhibitors and lifestyle adjustments. The drugs utilized include proton pump inhibitors (PPI), H2 antagonists, antibiotics, and other pharmaceuticals, which are distributed through various channels such as hospital pharmacies, private clinics, drug stores, retail pharmacies, and e-commerce.

The peptic ulcer market research report is one of a series of new reports that provides peptic ulcer market statistics, including peptic ulcer industry global market size, regional shares, competitors with a peptic ulcer market share, detailed peptic ulcer market segments, market trends and opportunities, and any further data you may need to thrive in the peptic ulcer industry. This peptic ulcer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 1-3 business days.